OURO FINO PARTICIPACOES E EMPR has a total of 11 patent applications. Its first patent ever was published in 2006. It filed its patents most often in Brazil, Mexico and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets biotechnology, pharmaceuticals and basic materials chemistry are SQZ BIOTECHNOLOGIES CO, ADVANTECH BIOSCIENCE FARM LTDA and GENLOCI BIOTECHNOLOGIES INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Brazil | 3 | |
#2 | Mexico | 3 | |
#3 | WIPO (World Intellectual Property Organization) | 3 | |
#4 | Panama | 1 | |
#5 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Basic materials chemistry | |
#4 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Microbiology | |
#5 | Reduction of greenhouse gas emissions | |
#6 | Refining | |
#7 | Candles | |
#8 | Peptides | |
#9 | Liquid hydrocarbon mixture production | |
#10 | Fermentation |
# | Name | Total Patents |
---|---|---|
#1 | Soccol Carlos Ricardo | 3 |
#2 | Neto Dolivar Coraucci | 3 |
#3 | Fernandes Nelson Henriques Jr | 2 |
#4 | Sercheli Ricardo Da Silva | 2 |
#5 | Coraucci Neto Dolivar | 2 |
#6 | Costa Jorge Alberto Vieira | 2 |
#7 | Knoerr Cristina Elisabete | 2 |
#8 | Ramos Angela Souza Da Fonseca | 1 |
#9 | Pepe De Moraes Lidia Maria | 1 |
#10 | Titze De Almeida Ricardo | 1 |
Publication | Filing date | Title |
---|---|---|
WO2009076737A1 | Production of recombinant bos taurus growth hormone with pichia pastoris | |
BRPI0806654A2 | production of recombinant bos taurus growth hormone | |
BRPI0804611A2 | process for biomass and protein production by microalgae | |
WO2008083453A1 | Process to produce biomass and proteins by microalgae | |
BRPI0700969A | composition for the treatment of bacterial and inflammatory conditions in pet animals | |
MX2008007773A | Veterinarian composition comprising an organic salt of levamisole in combination with at least one avermectine and/or milbemycine. |